Chapter 3. Unstable Angina and Non-ST-Elevation Myocardial Infarction

  1. Eli V. Gelfand Director of Ambulatory Cardiology1 and
  2. Christopher P. Cannon Senior Investigator Associate Professor2,3,4
  1. Eli V. Gelfand Director of Ambulatory Cardiology1 and
  2. Christopher P. Cannon Senior Investigator Associate Professor2,3,4

Published Online: 9 APR 2009

DOI: 10.1002/9780470745465.ch3

Management of Acute Coronary Syndromes

Management of Acute Coronary Syndromes

How to Cite

Gelfand, E. V. and Cannon, C. P. (2009) Unstable Angina and Non-ST-Elevation Myocardial Infarction, in Management of Acute Coronary Syndromes (eds E. V. Gelfand and C. P. Cannon), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470745465.ch3

Editor Information

  1. 1

    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

  2. 2

    TIMI Study Group, Boston, Massachusetts, USA

  3. 3

    Brigham and Women's Hospital, Boston, Massachusetts, USA

  4. 4

    Harvard Medical School, Boston, Massachusetts, USA

Author Information

  1. 1

    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

  2. 2

    TIMI Study Group, Boston, Massachusetts, USA

  3. 3

    Brigham and Women's Hospital, Boston, Massachusetts, USA

  4. 4

    Harvard Medical School, Boston, Massachusetts, USA

Publication History

  1. Published Online: 9 APR 2009
  2. Published Print: 17 APR 2009

ISBN Information

Print ISBN: 9780470725573

Online ISBN: 9780470745465

SEARCH

Keywords:

  • unstable angina and non-ST-elevation myocardial infarction;
  • UA/NSTEMI including cardioembolic disease;
  • general strategies in UA/NSTEMI management;
  • UA/NSTEMI and clinical risk profiles;
  • risk stratification of patients with UA/NSTEMI;
  • TIMI Risk Score for UA/NSTEMI in predicting short-term adverse events in UA/NSTEMI;
  • pharmacologic treatment of ischemia in UA/NSTEMI;
  • intraaortic balloon counterpulsation (IABP) for refractory ischemia;
  • calcium channel blockers (CCB) as direct coronary vasodilators;
  • antiplatelet therapy in UA/NSTEMI

Summary

This chapter contains sections titled:

  • Introduction

  • Causes of UA/NSTEMI

  • Presentation of UA/NSTEMI

  • General strategies in management of UA/NSTEMI

  • Risk stratification of patients with UA/NSTEMI

  • Initial management of UA/NSTEMI in the emergency department

  • Pharmacologic treatment of ischemia in UA/NSTEMI

  • Invasive versus conservative strategy

  • Antiplatelet therapy in UA/NSTEMI

  • Fibrinolysis in UA/NSTEMI

  • Early lipid-lowering therapy in patients with UA/NSTEMI

  • Predischarge noninvasive risk stratification after UA/NSTEMI

  • Overall management of UA/NSTEMI

  • References